Becton Dickinson and : BD, City of Hope to Offer Pharmacy Residency Program for Medication-Use Safety and Policy

New program to equip future pharmacists with industry exposure and hands-on experience with medication dispensing technology

FRANKLIN LAKES, N.J. (May 6, 2024) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new pharmacist residency program in collaboration with City of Hope, one of the largest cancer research and treatment organizations in the United States.

As part of a post-graduate clinical training program at City of Hope, one pharmacy resident per year will have the unique opportunity to gain a year of invaluable experience in the medical technology industry working with BD's Medication Management Solutions and Medication Delivery Solutions businesses.

"Sharing knowledge, skills and experiences to prepare the next generation of pharmacists is a core element of the oath of a pharmacist," Craig Greszler, PharmD, MBA, BCSCP, senior manager of Medical Affairs for BD and residency program preceptor. "The required industry and health-system research collaboration, professional relationships and invaluable transferrable skills pharmacy residents will gain through this robust program will serve them well as they enter their careers, regardless of the setting in which they choose to practice."

During the 12-month program, BD will provide real-world opportunities for one City of Hope pharmacy resident who will also complete two longer block rotations with BD. The resident will work under the supervision of experienced BD preceptors and clinicians and complete rotations with a range of business functions, including medical affairs, research and development, quality and risk management, and marketing.

The City of Hope resident will also have the opportunity to gain hands-on experience with pharmacy automation and medication management technology across a variety of care settings, including automated dispensing cabinets, vial-filling robots, technology-assisted workflow devices, closed system transfer devices and clinical decision-support technology. Spending time in both a health system environment and within the medical technology industry will provide the resident with a unique perspective of medication safety at both the local and global levels, fostering a skillset few pharmacists possess. As part of this experience, each resident will conduct a joint City of Hope-BD research project, contributing to a growing body of real-world evidence.

"This new pharmacy program will provide a competitive edge for our pharmacy residents," said Dr. Wafa Samara, City of Hope chief pharmacy officer. "City of Hope's goal is to transform the future of cancer care by providing outstanding patient care, conducting innovative research and offering vital education programs. We deliver best-in-class pharmaceutical care compassionately, safely and through evidence-based practice."

City of Hope began operating an ASHP-accredited pharmacy residency program in 1984 and is committed to patient-centered care rooted in education and research, efficiency optimization, talent acquisition and inspiring innovation.

# # #

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

Contacts:

Media:

Hallie Nicholson
Associate Director, Communications
760.201.6604
[e-mail]

Investors:

Adam Reiffe
Senior Director, Investor Relations
201.847.6927
[e-mail]